Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cephalon/Cima Merger Contingent On Granting Generic Actiq License To Barr

This article was originally published in The Pink Sheet Daily

Executive Summary

Barr's generic version of Actiq would enter the market when FDA approves Cima's fentanyl product, but no later than February 2007. The companies expect the merger to close in the next few days.

You may also be interested in...



Cephalon Receives “Approvable” Letter For Fentora

The company says it will respond to FDA by the end of July; additional safety and efficacy data are not required for the fentanyl buccal tablet.

Cephalon Receives “Approvable” Letter For Fentora

The company says it will respond to FDA by the end of July; additional safety and efficacy data are not required for the fentanyl buccal tablet.

Cephalon And Barr Reach Patent Settlements For Provigil, Actiq

Barr could gain up to two months of exclusivity for its Actiq generic.

Related Content

Topics

UsernamePublicRestriction

Register

OM003971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel